Bladder Cancer - Pipeline Review, H2 2015 Summary Global Markets Directs, Bladder Cancer - Pipeline Review, H2 2015, provides an overview of the Bladder Cancers therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Bladder Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are... Research Beam Model: Research Beam Product ID: 327805 2000 USD New
Bladder Cancer - Pipeline Review, H2 2015
 
 

Bladder Cancer - Pipeline Review, H2 2015

  • Category : Healthcare
  • Published On : July   2015
  • Pages : 508
  • Publisher : Global Markets Direct
 
 
 
Bladder Cancer - Pipeline Review, H2 2015

Summary

Global Markets Directs, Bladder Cancer - Pipeline Review, H2 2015, provides an overview of the Bladder Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bladder Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bladder Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bladder Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bladder Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bladder Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 8
List of Figures 11
Introduction 12
Global Markets Direct Report Coverage 12
Bladder Cancer Overview 13
Therapeutics Development 14
Pipeline Products for Bladder Cancer - Overview 14
Pipeline Products for Bladder Cancer - Comparative Analysis 15
Bladder Cancer - Therapeutics under Development by Companies 16
Bladder Cancer - Therapeutics under Investigation by Universities/Institutes 24
Bladder Cancer - Pipeline Products Glance 26
Late Stage Products 26
Clinical Stage Products 27
Early Stage Products 28
Bladder Cancer - Products under Development by Companies 29
Bladder Cancer - Products under Investigation by Universities/Institutes 37
Bladder Cancer - Companies Involved in Therapeutics Development 38
Advaxis, Inc. 38
Alligator Bioscience AB 39
Alnylam Pharmaceuticals, Inc. 40
Altor BioScience Corporation 41
AndroScience Corporation 42
APIM Therapeutics AS 43
Arno Therapeutics, Inc. 44
Ascenta Therapeutics, Inc. 45
Astellas Pharma Inc. 46
AstraZeneca Plc 47
AuraSense Therapeutics, LLC 48
AVEO Pharmaceuticals, Inc. 49
AvidBiotics Corp. 50
Bavarian Nordic A/S 51
Bayer AG 52
BioCancell Ltd 53
Bioncotech Therapeutics S.L. 54
Biotest AG 55
cCAM Biotherapeutics Ltd. 56
Celgene Corporation 57
Celldex Therapeutics, Inc. 58
Cold Genesys, Inc. 59
Daiichi Sankyo Company, Limited 60
DormaTarg, Inc. 61
Eisai Co., Ltd. 62
Eli Lilly and Company 63
EntreChem, S.L. 64
Esperance Pharmaceuticals, Inc. 65
Evotec AG 66
F. Hoffmann-La Roche Ltd. 67
Gene Signal International SA 68
Genmab A/S 69
GlaxoSmithKline Plc 70
Heat Biologics, Inc. 71
Horizon Pharma Plc 72
Hutchison MediPharma Limited 73
Idera Pharmaceuticals, Inc. 74
Immunomedics, Inc. 75
Immupharma Plc 76
ImmuRx, Inc. 77
Ludwig Institute For Cancer Research Ltd 78
MacroGenics, Inc. 79
Marina Biotech, Inc. 80
Meabco A/S 81
MedImmune, LLC 82
Merck & Co., Inc. 83
Millennium Pharmaceuticals, Inc. 84
Mirati Therapeutics Inc. 85
NuCana BioMed Limited 86
Omeros Corporation 87
Oncogenex Pharmaceuticals, Inc. 88
Oncolytics Biotech Inc. 89
Oncopeptides AB 90
Ono Pharmaceutical Co., Ltd. 91
Optimum Therapeutics, LLC 92
Panacela Labs, Inc. 93
Pfizer Inc. 94
Pharma Mar, S.A. 95
Polaris Pharmaceuticals, Inc. 96
PsiOxus Therapeutics Limited 97
Qu Biologics Inc. 98
Quest PharmaTech Inc. 99
Samyang Holdings Corporation 100
Sanofi 101
Serometrix, LLC 102
Shionogi & Co., Ltd. 103
Sorrento Therapeutics, Inc. 104
Spectrum Pharmaceuticals, Inc. 105
Stemline Therapeutics, Inc. 106
Sumitomo Dainippon Pharma Co., Ltd. 107
Sun Pharma Advanced Research Company Ltd. 108
Synta Pharmaceuticals Corp. 109
TARIS BioMedical, Inc. 110
Telesta Therapeutics Inc. 111
Telormedix SA 112
Theravectys SA 113
TheRyte Limited 114
Tolero Pharmaceuticals, Inc. 115
Transgene SA 116
Vakzine Projekt Management GmbH 117
Vaxeal Holding SA 118
Viralytics Ltd. 119
Viventia Biotechnologies Inc. 120
Bladder Cancer - Therapeutics Assessment 121
Assessment by Monotherapy Products 121
Assessment by Combination Products 122
Assessment by Target 123
Assessment by Mechanism of Action 128
Assessment by Route of Administration 132
Assessment by Molecule Type 134
Drug Profiles 136
ACP-196 - Drug Profile 136
ADC-1013 - Drug Profile 138
afuresertib hydrochloride + trametinib dimethyl sulfoxide - Drug Profile 140
aganirsen - Drug Profile 141
ALT-801 - Drug Profile 143
ALT-803 - Drug Profile 145
amrubicin hydrochloride - Drug Profile 147
Antibody to Inhibit TYRO-3 for Bladder Cancer - Drug Profile 149
Antisense Oligonucleotides for Bladder Cancer - Drug Profile 150
Antisense RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer - Drug Profile 151
apatorsen - Drug Profile 153
apaziquone - Drug Profile 155
APL-1202 - Drug Profile 157
APTA-012 - Drug Profile 158
AR-42 - Drug Profile 159
ASC-JM.Z1 - Drug Profile 161
ASG-15ME - Drug Profile 162
AST-008 - Drug Profile 163
AT-406 - Drug Profile 164
atezolizumab - Drug Profile 167
ATX-101 - Drug Profile 171
AV-203 - Drug Profile 172
AZD-4547 - Drug Profile 173
AZD-5312 - Drug Profile 175
B-701 - Drug Profile 176
BAY-1163877 - Drug Profile 177
BC-819 - Drug Profile 178
Biologic for Superficial Bladder Cancer - Drug Profile 180
BO-110 - Drug Profile 181
BPC-1 - Drug Profile 182
BV-2711 - Drug Profile 183
CDX-1401 - Drug Profile 184
Cell Therapy for Bladder Cancer - Drug Profile 186
Cell Therapy to Target HER2 for Oncology - Drug Profile 187
CG-0070 - Drug Profile 188
CM-24 - Drug Profile 190
CV-301 - Drug Profile 191
CVA-21 - Drug Profile 193
DAB-389EGF - Drug Profile 197
Dendritic Cell Therapy to Target HER-2 for Oncology - Drug Profile 198
docetaxel - Drug Profile 199
Drug for NMIBC - Drug Profile 200
Drugs to Inhibit FGFR3 for Bladder Cancer - Drug Profile 201
Drugs to Inhibit TYRO-3 for Bladder Cancer - Drug Profile 202
dsP21-322-2'F - Drug Profile 203
DT-310 - Drug Profile 204
DT-320 - Drug Profile 205
DT-330 - Drug Profile 207
durvalumab + tremelimumab - Drug Profile 208
EC-7072 - Drug Profile 210
enadenotucirev - Drug Profile 211
enoblituzumab - Drug Profile 213
EP-400 - Drug Profile 215
eribulin mesylate - Drug Profile 216
erlotinib hydrochloride - Drug Profile 221
GSK-2849330 - Drug Profile 224
HMPL-453 - Drug Profile 225
HuMax-TF-ADC - Drug Profile 226
ICT-2700 - Drug Profile 228
imiquimod - Drug Profile 229
IMO-2055 - Drug Profile 230
indatuximab ravtansine - Drug Profile 232
interferon gamma-1b - Drug Profile 234
IPP-204106 - Drug Profile 237
JAAF-11 - Drug Profile 239
lenalidomide - Drug Profile 240
Lm-LLO-ISG15 - Drug Profile 245
lurbinectedin - Drug Profile 247
MDNA-55 - Drug Profile 250
MDR-09521 - Drug Profile 251
Melflufen - Drug Profile 252
mitomycin SR - Drug Profile 254
MMD-37K - Drug Profile 256
mocetinostat - Drug Profile 257
Monoclonal Antibodies to Inhibit VISTA for Bladder Cancer - Drug Profile 260
Monoclonal Antibody to Inhibit EGFR for Superficial Bladder Cancer - Drug Profile 261
MVAME-03 - Drug Profile 262
MVXONCO-1 - Drug Profile 263
nivolumab - Drug Profile 264
NUC-1031 - Drug Profile 271
OGX-225 - Drug Profile 273
oportuzumab monatox - Drug Profile 274
paclitaxel - Drug Profile 276
paclitaxel albumin bound - Drug Profile 278
paclitaxel albumin free - Drug Profile 281
patritumab - Drug Profile 282
pegargiminase - Drug Profile 284
pelareorep - Drug Profile 287
pembrolizumab - Drug Profile 292
QBECP-SSI - Drug Profile 300
rAd-IFN - Drug Profile 301
ramucirumab - Drug Profile 303
recMAGE-A3 + AS15 - Drug Profile 309
Recombinant BCG - Pertussis Vaccine - Drug Profile 311
Recombinant Protein for Oncology and Infectious Disease - Drug Profile 312
RNAi Oligonucleotide to Inhibit TYRO-3 for Bladder Cancer - Drug Profile 313
S-588410 - Drug Profile 314
sacituzumab govitecan - Drug Profile 315
sapanisertib - Drug Profile 316
SAR-408701 - Drug Profile 318
SGT-94 - Drug Profile 319
sirolimus albumin-bound - Drug Profile 320
SL-052 - Drug Profile 322
SL-601 - Drug Profile 324
Small molecule for Bladder Cancer - Drug Profile 325
Small Molecule to Antagonize GPR87 for Cancer - Drug Profile 326
Small Molecule to Inhibit TDO-2 for Cancer - Drug Profile 327
Small Molecule to Inhibit TYRO3 for Bladder Cancer - Drug Profile 328
Small Molecules to Activate Caspase 3 and Caspase 9 for Bladder and Urinary Tract Cancer - Drug Profile 329
Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile 330
STA-128666 - Drug Profile 331
sunitinib malate - Drug Profile 333
suramin hexasodium - Drug Profile 337
SVX-1 - Drug Profile 339
SX-MTR1 - Drug Profile 340
TD-210 - Drug Profile 341
temsirolimus - Drug Profile 342
TF-011 Monomethyl Auristatin E - Drug Profile 344
TG-6002 - Drug Profile 345
THR-53 - Drug Profile 346
TMX-202 - Drug Profile 347
TP-3654 - Drug Profile 348
TT-16 - Drug Profile 349
Urocidin - Drug Profile 350
Vaccine for Bladder Cancer - Drug Profile 352
Vaccine to Target NY-ESO-1 for Oncology - Drug Profile 353
vemurafenib - Drug Profile 354
vesigenurtucel-L - Drug Profile 357
VPM-1002 - Drug Profile 358
Bladder Cancer - Recent Pipeline Updates 360
Bladder Cancer - Dormant Projects 482
Bladder Cancer - Discontinued Products 488
Bladder Cancer - Product Development Milestones 489
Featured News & Press Releases 489
Appendix 498
Methodology 498
Coverage 498
Secondary Research 498
Primary Research 498
Expert Panel Validation 498
Contact Us 498
Disclaimer 499

List Of Tables
List of Tables
Number of Products under Development for Bladder Cancer, H2 2015 23
Number of Products under Development for Bladder Cancer - Comparative Analysis, H2 2015 24
Number of Products under Development by Companies, H2 2015 26
Number of Products under Development by Companies, H2 2015 (Contd..1) 27
Number of Products under Development by Companies, H2 2015 (Contd..2) 28
Number of Products under Development by Companies, H2 2015 (Contd..3) 29
Number of Products under Development by Companies, H2 2015 (Contd..4) 30
Number of Products under Development by Companies, H2 2015 (Contd..5) 31
Number of Products under Investigation by Universities/Institutes, H2 2015 34
Comparative Analysis by Late Stage Development, H2 2015 35
Comparative Analysis by Clinical Stage Development, H2 2015 36
Comparative Analysis by Early Stage Development, H2 2015 37
Products under Development by Companies, H2 2015 38
Products under Development by Companies, H2 2015 (Contd..1) 39
Products under Development by Companies, H2 2015 (Contd..2) 40
Products under Development by Companies, H2 2015 (Contd..3) 41
Products under Development by Companies, H2 2015 (Contd..4) 42
Products under Development by Companies, H2 2015 (Contd..5) 43
Products under Development by Companies, H2 2015 (Contd..6) 44
Products under Development by Companies, H2 2015 (Contd..7) 45
Products under Investigation by Universities/Institutes, H2 2015 46
Bladder Cancer - Pipeline by Advaxis, Inc., H2 2015 47
Bladder Cancer - Pipeline by Alligator Bioscience AB, H2 2015 48
Bladder Cancer - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015 49
Bladder Cancer - Pipeline by Altor BioScience Corporation, H2 2015 50
Bladder Cancer - Pipeline by AndroScience Corporation, H2 2015 51
Bladder Cancer - Pipeline by APIM Therapeutics AS, H2 2015 52
Bladder Cancer - Pipeline by Arno Therapeutics, Inc., H2 2015 53
Bladder Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2015 54
Bladder Cancer - Pipeline by Astellas Pharma Inc., H2 2015 55
Bladder Cancer - Pipeline by AstraZeneca Plc, H2 2015 56
Bladder Cancer - Pipeline by AuraSense Therapeutics, LLC, H2 2015 57
Bladder Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 58
Bladder Cancer - Pipeline by AvidBiotics Corp., H2 2015 59
Bladder Cancer - Pipeline by Bavarian Nordic A/S, H2 2015 60
Bladder Cancer - Pipeline by Bayer AG, H2 2015 61
Bladder Cancer - Pipeline by BioCancell Ltd, H2 2015 62
Bladder Cancer - Pipeline by Bioncotech Therapeutics S.L., H2 2015 63
Bladder Cancer - Pipeline by Biotest AG, H2 2015 64
Bladder Cancer - Pipeline by cCAM Biotherapeutics Ltd., H2 2015 65
Bladder Cancer - Pipeline by Celgene Corporation, H2 2015 66
Bladder Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2015 67
Bladder Cancer - Pipeline by Cold Genesys, Inc., H2 2015 68
Bladder Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 69
Bladder Cancer - Pipeline by DormaTarg, Inc., H2 2015 70
Bladder Cancer - Pipeline by Eisai Co., Ltd., H2 2015 71
Bladder Cancer - Pipeline by Eli Lilly and Company, H2 2015 72
Bladder Cancer - Pipeline by EntreChem, S.L., H2 2015 73
Bladder Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2015 74
Bladder Cancer - Pipeline by Evotec AG, H2 2015 75
Bladder Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 76
Bladder Cancer - Pipeline by Gene Signal International SA, H2 2015 77
Bladder Cancer - Pipeline by Genmab A/S, H2 2015 78
Bladder Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015 79
Bladder Cancer - Pipeline by Heat Biologics, Inc., H2 2015 80
Bladder Cancer - Pipeline by Horizon Pharma Plc, H2 2015 81
Bladder Cancer - Pipeline by Hutchison MediPharma Limited, H2 2015 82
Bladder Cancer - Pipeline by Idera Pharmaceuticals, Inc., H2 2015 83
Bladder Cancer - Pipeline by Immunomedics, Inc., H2 2015 84
Bladder Cancer - Pipeline by Immupharma Plc, H2 2015 85
Bladder Cancer - Pipeline by ImmuRx, Inc., H2 2015 86
Bladder Cancer - Pipeline by Ludwig Institute For Cancer Research Ltd, H2 2015 87
Bladder Cancer - Pipeline by MacroGenics, Inc., H2 2015 88
Bladder Cancer - Pipeline by Marina Biotech, Inc., H2 2015 89
Bladder Cancer - Pipeline by Meabco A/S, H2 2015 90
Bladder Cancer - Pipeline by MedImmune, LLC, H2 2015 91
Bladder Cancer - Pipeline by Merck & Co., Inc., H2 2015 92
Bladder Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 93
Bladder Cancer - Pipeline by Mirati Therapeutics Inc., H2 2015 94
Bladder Cancer - Pipeline by NuCana BioMed Limited, H2 2015 95
Bladder Cancer - Pipeline by Omeros Corporation, H2 2015 96
Bladder Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2015 97
Bladder Cancer - Pipeline by Oncolytics Biotech Inc., H2 2015 98
Bladder Cancer - Pipeline by Oncopeptides AB, H2 2015 99
Bladder Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 100
Bladder Cancer - Pipeline by Optimum Therapeutics, LLC, H2 2015 101
Bladder Cancer - Pipeline by Panacela Labs, Inc., H2 2015 102
Bladder Cancer - Pipeline by Pfizer Inc., H2 2015 103
Bladder Cancer - Pipeline by Pharma Mar, S.A., H2 2015 104
Bladder Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015 105
Bladder Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2015 106
Bladder Cancer - Pipeline by Qu Biologics Inc., H2 2015 107
Bladder Cancer - Pipeline by Quest PharmaTech Inc., H2 2015 108
Bladder Cancer - Pipeline by Samyang Holdings Corporation, H2 2015 109
Bladder Cancer - Pipeline by Sanofi, H2 2015 110
Bladder Cancer - Pipeline by Serometrix, LLC, H2 2015 111
Bladder Cancer - Pipeline by Shionogi & Co., Ltd., H2 2015 112
Bladder Cancer - Pipeline by Sorrento Therapeutics, Inc., H2 2015 113
Bladder Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 114
Bladder Cancer - Pipeline by Stemline Therapeutics, Inc., H2 2015 115
Bladder Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 116
Bladder Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015 117
Bladder Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2015 118
Bladder Cancer - Pipeline by TARIS BioMedical, Inc., H2 2015 119
Bladder Cancer - Pipeline by Telesta Therapeutics Inc., H2 2015 120
Bladder Cancer - Pipeline by Telormedix SA, H2 2015 121
Bladder Cancer - Pipeline by Theravectys SA, H2 2015 122
Bladder Cancer - Pipeline by TheRyte Limited, H2 2015 123
Bladder Cancer - Pipeline by Tolero Pharmaceuticals, Inc., H2 2015 124
Bladder Cancer - Pipeline by Transgene SA, H2 2015 125
Bladder Cancer - Pipeline by Vakzine Projekt Management GmbH, H2 2015 126
Bladder Cancer - Pipeline by Vaxeal Holding SA, H2 2015 127
Bladder Cancer - Pipeline by Viralytics Ltd., H2 2015 128
Bladder Cancer - Pipeline by Viventia Biotechnologies Inc., H2 2015 129
Assessment by Monotherapy Products, H2 2015 130
Assessment by Combination Products, H2 2015 131
Number of Products by Stage and Target, H2 2015 133
Number of Products by Stage and Mechanism of Action, H2 2015 138
Number of Products by Stage and Route of Administration, H2 2015 142
Number of Products by Stage and Molecule Type, H2 2015 144
Bladder Cancer Therapeutics - Recent Pipeline Updates, H2 2015 369
Bladder Cancer - Dormant Projects, H2 2015 491
Bladder Cancer - Dormant Projects (Contd..1), H2 2015 492
Bladder Cancer - Dormant Projects (Contd..2), H2 2015 493
Bladder Cancer - Dormant Projects (Contd..3), H2 2015 494
Bladder Cancer - Dormant Projects (Contd..4), H2 2015 495
Bladder Cancer - Dormant Projects (Contd..5), H2 2015 496
Bladder Cancer - Discontinued Products, H2 2015 497

List Of Figures
List of Figures
Number of Products under Development for Bladder Cancer, H2 2015 23
Number of Products under Development for Bladder Cancer - Comparative Analysis, H2 2015 24
Number of Products under Development by Companies, H2 2015 25
Number of Products under Investigation by Universities/Institutes, H2 2015 33
Comparative Analysis by Late Stage Development, H2 2015 35
Comparative Analysis by Clinical Stage Development, H2 2015 36
Comparative Analysis by Early Stage Products, H2 2015 37
Assessment by Monotherapy Products, H2 2015 130
Assessment by Combination Products, H2 2015 131
Number of Products by Top 10 Targets, H2 2015 132
Number of Products by Stage and Top 10 Targets, H2 2015 132
Number of Products by Top 10 Mechanism of Actions, H2 2015 137
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 137
Number of Products by Top 10 Routes of Administration, H2 2015 141
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 141
Number of Products by Top 10 Molecule Types, H2 2015 143
Number of Products by Stage and Top 10 Molecule Types, H2 2015 143
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 

Related Reports

REQUEST SAMPLE    ASK FOR DISCOUNT